HBOT Conversations:
Elena Schertz & Tom Fox
(Part 5) – COVID
Elena Schetz, NP is the nurse practitioner, and Tom Fox is the Safety Director at Extivita-RTP. Extivita-RTP offers a positive environment for healing, and they encourage anyone seeking a better quality of life to come visit them and experience for themselves the wonder of Hyperbaric Oxygen Therapy.
Watch the Podcast
In a Special 5-part series with Extivita’s Nurse Practitioner, Elena Schertz, and Safety Director, Tom Fox, we dive into the extraordinary powers of HBOT, and the healing they have witnessed for a variety of conditions. The following segments prelude this episode:
Part 1 – HBOT for PTSD (veteran focus)
Part 2 – Concussions & HBOT
Part 3 – Healing Heart Disease with HBOT
Part 4 – Cancer & Cerebral Palsy
In this final episode, we discuss COVID, and how long-haulers are finally finding relief in Hyperbaric Oxygen Therapy.
Host di Girolamo starts the conversation explaining that people who suffer from brain fog, oxygen shortages, and fatigue are discovering that HBOT is providing them relief. Tom chimes in that early oxygen delivery and pre-hospitalization was something the Italians saw in COVID as it progressed, and they discovered the role of HBOT in the acute care stage of COVID. The Italians witnessed patients who were heading in the wrong direction being released from the hospital after only 5 hyperbaric oxygen therapy treatments. The role of hyperbaric oxygen in COVID cases is incredible. Tom reminds us that only about 1,400 of the 6,500 hospital in the US have HBOT chambers, meaning that it is not a standard of care.
Studies out of Britain state ten HBOT treatments are ideal for COVID patients to witness a complete turn-around, and they get their lives back in two weeks. Tom explains that 40% of their patients are long-haul COVID and they’re coming to a HBOT clinic because there’s no other option. Hyperbaric Oxygen Therapy DOES return a COVID patient back to their baseline.
Chronic, or long-haul COVID patients (someone who has been dealing with symptoms for months or years) will likely need more treatments, but there is still so much hope. Elena says that the long-haul COVID patients who have come to see her have all improved. Elena has seen some long-haul COVID patients get better in as little as 4 treatments, and then there are some patients who need 40 treatments. Just like how everyone responds to COVID differently, the same goes for HBOT to treat COVID. There’s no magic number; but if you get in quicker then it’s more likely you won’t need as many treatments. In the end, it’s important to simply know that HBOT hands-down does help COVID patients, and it’s worth a try.
“Elena states, “I want to say it’s kind of easily fixed, you know, the fatigue. I’ve seen it over and over again. Until somebody comes in and disputes that or I see that, then I’ll keep saying, yeah, it really is very effective. I’ve seen it 100% of the time. It really is 100%”
And then there are the vaccine injuries. Tom stresses that he believes in the power of vaccines, he his definitely not an anti-vaxxer. But, when he looks at what’s going on in the world today it’s concerning. If you were to document a vaccine injury right now, it’s almost like the kiss of death to anybody that reaches out to challenge vaccines.
“We’re downplaying the VAER system. You know, in the current vaccine, with the number of reactions that we’ve seen with the current vaccine, previous vaccines would have been taken off the market.
HBOT News appreciates Tom and Elena joining us in our Conversations podcast and invites you to check out their clinic, Extivita-RTP if you are ever in the Raleigh, NC area.
Guests
Elena Schertz, NP - Clinic Manager at Extivita RTP
Elena worked as a nurse in the pediatric oncology, cardiac, and surgical units at UNC hospitals for 15 years before deciding to work in integrative medicine. After years of working as a nurse, she decided to pursue her graduate degree, completing her masters with honors. She is board certified as a Family Nurse Practitioner (FNP) through the American Nurses Credentialing Center.
Elena’s passion for integrative medicine comes from her knowledge that the mind, body and psych/social/spiritual systems are not separate. The focus of Elena’s practice is to approach each of her patient’s healing process from the perspective of the whole, supported and grounded in safety and evidence-based medicine. She also maintains close consultative relationships with experts in the field to promote and enhance wellness for her patients. Elena joined the wonderful Extivita team in March 2019 and is thrilled to be a part of advancing health and wellness through hyperbaric medicine.
Thomas M. Fox, MAS,MS, CHT - Safety Director at Extivita RTP
Tom joined the Extivita team in 2022 as the Safety Director, helping Extivita to maintain a healthy and safe environment for exceptional patient care.
Extivita-RTP – Hyperbaric Oxygen Therapy Clinic
2012-D TW Alexander Drive
Durham, NC 27709
919-354-3775
919-354-3776
contact@extivita.org
https://www.extivita.org/
Subscribe Now, It’s Free!
Recent HBOT News
Healing of spongiosus-cutaneous fistula with Hyperbaric Oxygen Therapy (HBOT): a case report.
Abstract: We present a case of a spongiosus-cutaneous fistula in a 39-year-old man with recurrent episodes of cutaneous abscess in dorsal middle third penis (5 - 3 cm) treated with Hyperbaric Oxygen Therapy (HBOT). After emptying nodular abscess, the patient was...
Clinical Trial – Caudal Block,Saddle Block, Anorectal Surgery
Anorectal surgery includes pilonidal sinus, hemorrhoidectomy, anal fissure, and anal fistula
operations. Various surgical and anesthetic techniques have been used to increase the level
of analgesia in perioperative period and decrease the length of stay in the hospital. In this
study, investigators investigate the effects of routinely applied anesthesia techniques
during anorectal surgery, caudal block and saddle block, on patients’ perioperative
hemodynamic values, sensory and motor block levels, and postoperative pain scores.
Clinical Trial – Hyperbaric Oxygen Therapy for Ulcerative Colitis Flares
Ulcerative colitis (UC) is a chronic inflammatory bowel disease associated with recurrent
mucosal inflammation. Clinically, the disease is characterized by bloody diarrhea, abdominal
pain, and constitutional symptoms such as fever and weight loss. Treatment strategies vary
based on disease activity and target various aspects of the inflammatory cascade. Options
include: anti-inflammatory drugs (mesalamine), immunosuppressive or modulatory medications
(corticosteroids, thiopurines, cyclosporine) and biologic agents (Anti-TNF). Disease severity
can be wide ranging, and nearly 25% of UC patients are hospitalized for acute severe disease.
Of these patients, 30% will undergo colectomy after the acute episode, a quarter of which
will experience post-operative complications. Although there has been great progress in
treatment of UC over the past decade, even with the anti-TNF agent infliximab, the one-year
remission rate for patients not responding to conservative management is barely 20%.
Furthermore, corticosteroids have significant long-term consequences and immune suppressive
drugs such as 6-mercaptopurine, azathioprine and infliximab have been associated with serious
adverse events including life-threatening infections and lymphomas. With growing evidence
that the pathogenesis of UC is multi-factorial and involves a complex interaction of genetic
and environmental factors, newer treatment modalities are being evaluated to target the
mucosal immune response and mucosal inflammatory regulatory system.
Hyperbaric oxygen offers a promising new treatment option since it targets both tissue
hypoxia and inflammation. Recent small scales studies evaluating the impact of hyperbaric
oxygen treatment in acute ulcerative colitis flares demonstrated improved outcomes. The
mechanisms underlying the improvement are not known. In this study, we will treat ulcerative
colitis flares with hyperbaric oxygen and measure changes in both markers of tissue hypoxia
and inflammation. We hypothesize that hyperbaric oxygen will (a) improve outcomes, and (b)
show reductions in markers of both tissue hypoxia and inflammation.